157701-33-2

Usage

Uses

Used in Organic Synthesis:
N-(5-BROMO-2,3-DIHYDRO-1H-INDEN-6-YL)ACETAMIDE is used as a building block for the synthesis of more complex organic molecules. It is particularly useful in the creation of new compounds with potential applications in various fields.
Used in Pharmaceutical Research:
N-(5-BROMO-2,3-DIHYDRO-1H-INDEN-6-YL)ACETAMIDE is used as a research compound in the field of pharmaceuticals. It may have potential applications in the development of new drugs, although further research is needed to explore its therapeutic properties.
Used in Agrochemical Research:
N-(5-BROMO-2,3-DIHYDRO-1H-INDEN-6-YL)ACETAMIDE is also used in agrochemical research. It may have potential applications in the development of new pesticides or other agrochemical products, although further research is required to determine its effectiveness and safety.
Used in Laboratory Settings:
N-(5-BROMO-2,3-DIHYDRO-1H-INDEN-6-YL)ACETAMIDE is used in controlled laboratory settings for studying the reactivity of different functional groups. This helps researchers understand the chemical properties and potential applications of N-(5-BROMO-2,3-DIHYDRO-1H-INDEN-6-YL)ACETAMIDE.
It is important to handle N-(5-Bromo-2,3-dihydro-1H-inden-6-yl)acetamide with caution, as it may pose certain health hazards. Proper safety measures should be taken when working with this chemical compound in a laboratory setting.

Upstream product

• 59856-06-3 5-acetamidoindane 
• 7726-95-6 bromine 
• 64-19-7 acetic acid 
• 24425-40-9 indan-5-amine 
• 53474-09-2 6-bromo-2,3-dihydro-1H-inden-5-amine 
• 108-24-7 acetic anhydride 

Downstream Products

• 53474-09-2 6-bromo-2,3-dihydro-1H-inden-5-amine 
• 158205-18-6 5-Acetylamino-6-bromo-1-indanone 
• 1026064-29-8 C₁₈H₁₇NO₅S 
• 1026500-21-9 C₁₇H₁₄FNO₄S 
• 1028292-63-8 C₂₀H₂₁NO₄S 
• 1027552-90-4 C₁₉H₁₉NO₄S 
• 1027080-41-6 C₁₇H₁₄BrNO₄S 
• 1027933-91-0 C₁₇H₁₄FNO₄S 
• 1026500-55-9 C₁₇H₁₄FNO₄S 
• 1026814-94-7 C₁₈H₁₇NO₄S 
• 1027313-05-8 C₁₈H₁₇NO₄S 
• 1027155-51-6 C₁₇H₂₁NO₄S 

Relevant academic research and scientific papers

Synthesis of bromoaminoindane and bromoaminoindanone derivatives

The bromination reactions of 5-aminoindane, 5-acetamidoindane, and 5-acetamidoindan-1-one were investigated using NBS, molecular bromine and photobromination, and the optimum reaction conditions were presented. The reaction of 5-aminoindane with glacial acetic acid at reflux temperature resulted in the formation of 5-acetamidoindane in high yield. 5-Acetamidoindan-1-one was generated by the reaction of 5-acetamidoindane with CrO3 in acetic acid. Selective bromination at C-6 position of 5-acetamidoindane was achieved by treatment of title compound with bromine in acetic acid and thus afforded 5-acetamido-6-bromoindane. Further bromination reactions of bromoindanones were achieved in various reaction conditions.

Discovery of Potent Benzolactam IRAK4 Inhibitors with Robust in Vivo Activity

IRAK4 kinase activity transduces signaling from multiple IL-1Rs and TLRs to regulate cytokines and chemokines implicated in inflammatory diseases. As such, there is high interest in identifying selective IRAK4 inhibitors for the treatment of these disorders. We previously reported the discovery of potent and selective dihydrobenzofuran inhibitors of IRAK4. Subsequent studies, however, showed inconsistent inhibition in disease-relevant pharmacodynamic models. Herein, we describe application of a human whole blood assay to the discovery of a series of benzolactam IRAK4 inhibitors. We identified potent molecule 19 that achieves robust in vivo inhibition of cytokines relevant to human disease.

COMPOUNDS AND METHODS FOR IDO AND TDO MODULATION, AND INDICATIONS THEREFOR

Disclosed are compounds of Formula (I) and (Ia) or a pharmaceutically acceptable salt, a solvate, a tautomer, a stereoisomer or a deuterated analog thereof, wherein R4, R5, R6, and R7 are as described in any of the embodiments described in this disclosure; compositions thereof; and uses thereof.

PYRAZOLO[1,5a]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS

Compounds of Formula (I), Formula (II), Formula (III), Formula (IV), Formula (V), Formula (VI), Formula (VII), Formula (VIII), and methods of use as lnterleukin-1 Receptor Associated Kinase (IRAK4) inhibitors are described herein.

COMPOUNDS AND METHODS FOR IDO AND TDO MODULATION, AND INDICATIONS THEREFOR

Disclosed are compounds of Formula I (a) or a pharmaceutically acceptable salt, a solvate, a tautomer, an isomer or a deuterated analog thereof, wherein R4, R5, R6, R7, G1, G2 and Ring A are as described in any of the embodiments described in this disclosure; compositions thereof; and uses thereof.

PYRAZOLO[1,5a]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS

Compounds of Formula (0), Formula (I), and Formula (II) and methods of use as Interleukin-1 Receptor Associated Kinase (IRAK4) inhibitors are described herein.

BICYCLIC DERIVATIVES AND PHARMACEUTICAL COMPOSITION INCLUDING THE SAME

The present invention relates to a novel bicyclic derivative that has an inhibitory activity against sodium-glucose linked transporters (SGLTs) present in the intestines and kidneys, or a pharmaceutically acceptable salt, isomer, hydrate or solvate thereo

5, 6-RING ANNULATED INDOLE DERIVATIVES AND USE THEREOF

The present invention relates to 5,6-ring annulated indole derivatives of the formula (I), compositions comprising at least one 5,6-ring annulated indole derivatives, and methods of using the 5,6-ring annulated indole derivatives for treating or preventing a viral infection or a virus-related disorder in a patient.

A structure-guided approach to an orthogonal estrogen-receptor-based gene switch activated by ligands suitable for in vivo studies

A strategy to obtain a fully orthogonal estrogen-receptor-based gene switch responsive to molecules with acceptable pharmacological properties is presented. From a series of tetrahydrofluorenones active on the wild-type estrogen receptor (ER) an inactive